DOT1L Mutations as a Potential Predictor for Immune Checkpoint Inhibitor Efficacy in Non-Small-Cell Lung Cancer

被引：0
|
作者：
Li, G. [1 ,2 ]
Su, P. [3 ]
Wang, S. [4 ]
Zhang, Y. [4 ]
Pang, J. [4 ]
Ou, Q. [4 ]
Shao, Y. [4 ]
Yu, H. [5 ]
Wang, X. [1 ,2 ]
机构：
[1] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Chengdu, Peoples R China
[2] Chinese Acad Sci, Sichuan Translat Med Res Hosp, Chengdu, Peoples R China
[3] Hosp Chengdu Univ Tradit Chinese Med, Chengdu, Peoples R China
[4] Nanjing Geneseeq Technol Inc, Nanjing, Peoples R China
[5] Chengdu Jinniu Dist Peoples Hosp, Chengdu, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
DOT1L; Immune checkpoint inhibitors; Next-generation sequencing;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.21-17
引用
收藏
页码：S242 / S242
页数：1
相关论文
共 50 条
  • [31] PTPRD/PTPRT mutations as potential positive predictor for response of immune checkpoint inhibitors in non-small cell lung cancer (NSCLC).
    Zeng, Jian
    Wang, Guoqiang
    Yan, Zhengqing
    Zheng, Hao
    Li, Jianqiang
    Tao, Feng
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [32] Immune Checkpoint Inhibitors for Brain Metastases of Non-Small-Cell Lung Cancer
    Ashinuma, H.
    Shingyoji, M.
    Iuchi, T.
    Yoshida, Y.
    Setoguchi, T.
    Hasegawa, Y.
    Sakaida, T.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2420 - S2420
  • [33] The efficacy and safety of immune checkpoint inhibitor plus chemotherapy in patients with advanced non-small-cell lung cancer: a meta-analysis
    Li-Fang Meng
    Jian-Feng Huang
    Peng-Hui Luo
    Shang-Xiao Huang
    Han-Lei Wang
    Investigational New Drugs, 2022, 40 : 810 - 817
  • [34] Immune checkpoint inhibitor efficacy and safety in elderly non-small cell lung cancer patients
    Kubo, T.
    Watanabe, H.
    Ninomiya, K.
    Kudo, K.
    Minami, D.
    Murakami, E.
    Ochi, N.
    Ninomiya, T.
    Harada, D.
    Yasugi, M.
    Ichihara, E.
    Ohashi, K.
    Fujiwara, K.
    Hotta, K.
    Tabata, M.
    Maeda, Y.
    Kiura, K.
    ANNALS OF ONCOLOGY, 2018, 29
  • [35] Immune checkpoint inhibitor efficacy and safety in older non-small cell lung cancer patients
    Kubo, Toshio
    Watanabe, Hiromi
    Ninomiya, Kiichiro
    Kudo, Kenichiro
    Minami, Daisuke
    Murakami, Etsuko
    Ochi, Nobuaki
    Ninomiya, Takashi
    Harada, Daijiro
    Yasugi, Masayuki
    Ichihara, Eiki
    Ohashi, Kadoaki
    Rai, Kammei
    Fujiwara, Keiichi
    Hotta, Katsuyuki
    Tabata, Masahiro
    Maeda, Yoshinobu
    Kiura, Katsuyuki
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2020, 50 (12) : 1447 - 1453
  • [36] The efficacy and safety of immune checkpoint inhibitor plus chemotherapy in patients with advanced non-small-cell lung cancer: a meta-analysis
    Meng, Li-Fang
    Huang, Jian-Feng
    Luo, Peng-Hui
    Huang, Shang-Xiao
    Wang, Han-Lei
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (04) : 810 - 817
  • [37] Association Between Clinical Tumor Burden and Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer Reply
    Passaro, Antonio
    Spitaleri, Gianluca
    de Marinis, Filippo
    CLINICAL LUNG CANCER, 2020, 21 (05) : E415 - E416
  • [38] Clinical and laboratory predictors of immune checkpoint inhibitor efficacy in non-small cell lung cancer
    Christopoulos, P.
    Kohlhaeufl, J.
    Bozorgmehr, F.
    Kuon, J.
    Schneider, M.
    Neumann, O.
    Liersch, S.
    Heussel, C.
    Winter, H.
    Herth, F.
    Rieken, S.
    Muley, T.
    Meister, M.
    Bischoff, H.
    Lasitschka, F.
    Stenzinger, A.
    Thomas, M.
    ANNALS OF ONCOLOGY, 2018, 29
  • [39] Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system
    Grizzi, Giulia
    Caccese, Mario
    Gkountakos, Anastasios
    Carbognin, Luisa
    Tortora, Giampaolo
    Bria, Emilio
    Pilotto, Sara
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2017, 17 (12) : 1055 - 1069
  • [40] Machine learning-based predictors for immune checkpoint inhibitor therapy of non-small-cell lung cancer
    Wiesweg, M.
    Mairinger, F.
    Reis, H.
    Goetz, M.
    Walter, R. F. H.
    Hager, T.
    Metzenmacher, M.
    Eberhardt, W. E. E.
    McCutcheon, A.
    Koester, J.
    Stuschke, M.
    Aigner, C.
    Darwiche, K.
    Schmid, K. W.
    Rahmann, S.
    Schuler, M.
    ANNALS OF ONCOLOGY, 2019, 30 (04) : 655 - 657
12345